Association of SMAD4 loss with drug resistance in clinical cancer patients: A systematic meta-analysis

被引:9
作者
Xu, Wei [1 ]
Lee, Sau Har [2 ]
Qiu, Fengjun [1 ]
Zhou, Li [3 ]
Wang, Xiaoling [1 ]
Ye, Tingjie [1 ]
Hu, Xudong [1 ]
机构
[1] Shanghai Univ Tradit Chinese Med, Sch Basic Med Sci, Shanghai, Peoples R China
[2] Taylors Univ, Sch Biosci, Fac Hlth & Med Sci, Subang Jaya, Selangor, Malaysia
[3] ISoftStone Informat Technol Grp Co Ltd, Beijing, Peoples R China
来源
PLOS ONE | 2021年 / 16卷 / 05期
关键词
TGF-BETA; COLORECTAL-CANCER; GENE MUTATION; CHEMOTHERAPY; PROGNOSIS; EXPRESSION; MARKER;
D O I
10.1371/journal.pone.0250634
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Background Drug resistance frequently led to the failure of chemotherapy for malignant cancers, hence causing cancer relapse. Thus, understanding mechanism of drug resistance in cancer is vital to improve the treatment efficacy. Here, we aim to evaluate the association between SMAD4 expression and the drug resistance in cancers by performing a meta-analysis. Method Relevant studies detecting SMAD4 expression in cancer patients treated with chemo-drugs up till December 2020 were systematically searched in four common scientific databases using selected keywords. The pooled hazard ratio (HR) was the ratio of hazard rate between SMAD4(neg) population vs SMAD4(pos) population. The HRs and risk ratios (RRs) with 95% confidence intervals (CIs) were used to explore the association between SMAD4 expression losses with drug resistance in cancers. Result After an initial screening according to the inclusion and exclusion criteria, eleven studies were included in the meta-analysis. There were a total of 2092 patients from all the included studies in this analysis. Results obtained indicated that loss of SMAD4 expression was significantly correlated with drug resistance with pooled HRs (95% CI) of 1.23 (1.01-1.45), metastasis with pooled RRs (95% CI) of 1.10 (0.97-1.25) and recurrence with pooled RRs (95% CI) of 1.32 (1.06-1.64). In the subgroup analysis, cancer type, drug type, sample size and antibody brand did not affect the significance of association between loss of SMAD4 expression and drug resistance. In addition, there was no evidence of publication bias as suggested by Begg's test. Conclusion Findings from our meta-analysis demonstrated that loss of SMAD4 expression was correlated with drug resistance, metastasis and recurrence. Therefore, SMAD4 expression could be potentially used as a molecular marker for cancer resistance.
引用
收藏
页数:14
相关论文
共 50 条
  • [41] Smad4 loss in mice causes spontaneous head and neck cancer with increased genomic instability and inflammation
    Bornstein, Sophia
    White, Ruth
    Malkoski, Stephen
    Oka, Masako
    Han, Gangwen
    Cleaver, Timothy
    Reh, Douglas
    Andersen, Peter
    Gross, Neil
    Olson, Susan
    Deng, Chuxia
    Lu, Shi-Long
    Wang, Xiao-Jing
    JOURNAL OF CLINICAL INVESTIGATION, 2009, 119 (11) : 3408 - 3419
  • [42] Association between H3K4 methylation and cancer prognosis: A meta-analysis
    Li, Simin
    Shen, Luyan
    Chen, Ke-Neng
    THORACIC CANCER, 2018, 9 (07) : 794 - 799
  • [43] The association of comorbidities with administration of adjuvant chemotherapy in stage III colon cancer patients: a systematic review and meta-analysis
    Boakye, Daniel
    Nagrini, Rajini
    Ahrens, Wolfgang
    Haug, Ulrike
    Guenther, Kathrin
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2021, 13
  • [44] Association between bevacizumab with cancer drug therapies and drug-induced interstitial lung disease in patients with solid tumor: A systematic review and meta-analysis of randomized clinical trials
    Nozawa, Kazuki
    Takatsuka, Daiki
    Endo, Yuka
    Horisawa, Nanae
    Ozaki, Yuri
    Kataoka, Ayumi
    Kotani, Haruru
    Yoshimura, Akiyo
    Hattori, Masaya
    Sawaki, Masataka
    Iwata, Hiroji
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2022, 174
  • [45] The clinical prognostic value of lncRNA LINC00675 in cancer patients A meta-analysis
    Hua, Hao
    Wang, Jie
    Zhong, Pingyong
    Mou, Tinggang
    Liu, Pan
    Xie, Fei
    MEDICINE, 2021, 100 (16)
  • [46] Analysis of SMAD4 Aberrations in Chinese Patients with Non-Small-Cell Lung Cancer
    Huang, J.
    Xu, C.
    Wang, W.
    Zhang, Q.
    Zhou, Y.
    Zhuang, W.
    Zhu, Y.
    Huang, Z.
    Chen, Y.
    Chen, G.
    Fang, M.
    Lv, T.
    Song, Y.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S512 - S512
  • [47] MicroRNA-21 as a prognostic biomarker in patients with pancreatic cancer - A systematic review and meta-analysis
    Negoi, Ionut
    Hostiuc, Sorin
    Sartelli, Massimo
    Negoi, Ruxandra Irina
    Beuran, Mircea
    AMERICAN JOURNAL OF SURGERY, 2017, 214 (03) : 515 - 524
  • [48] Clinicopathological and prognostic significance of nestin expression in patients with breast cancer: a systematic review and meta-analysis
    Zhang, Xinyi
    Xing, Changsheng
    Guan, Wenting
    Chen, Lang
    Guo, Kai
    Yu, Anze
    Xie, Kai
    CANCER CELL INTERNATIONAL, 2020, 20 (01)
  • [49] Association of SMAD7 rs12953717 Polymorphism with Cancer: A Meta-Analysis
    Zhang, Hongtuan
    Ma, Hui
    Xu, Yong
    Li, Liang
    PLOS ONE, 2013, 8 (03):
  • [50] Clinical Outcome of Colorectal Cancer Patients with Concomitant Hypertension: A Systematic Review and Meta-Analysis
    Sur, Daniel
    Coroama, Constantin Ionut
    Audisio, Alessandro
    Fazio, Roberta
    Coroama, Maria
    Lungulescu, Cristian Virgil
    JOURNAL OF PERSONALIZED MEDICINE, 2024, 14 (05):